Clinical Study of Polymyxin B Combined with Carbapenem Antibiotics in the Treatment of Carbapenem-resistant Klebsiella Pneumoniae Infection

Objective: To investigate the antibacterial activity and clinical efficacy of polymyxin B combined with carbapenem antibiotics against carbapenem resistant Klebsiella pneumoniae (CRKP), and analyze its medication safety. Methods: By reviewing relevant literature, the mechanism of action of polymyxin B combined with carbapenem antibiotics was analyzed, including complementary targets and synergistic cell membrane damage. At the same time, based on comprehensive clinical research reports, evaluate the impact of different drug combinations, infection sites, populations, and treatment courses on treatment efficacy, as well as safety risks such as nephrotoxicity and neurotoxicity. The primary target audience consists of patients infected with CRKP, involving different age groups, infection sites, and treatment plans. Results: The combination of polymyxin B and carbapenem antibiotics can enhance the antibacterial activity against CRKP through multiple mechanisms. However, clinical treatment efficacy is influenced by multiple factors, and there are safety risks involved. Conclusion: Therefore, when using combination therapy, it is necessary to develop a reasonable treatment plan based on the patient's condition, infection site, and drug characteristics, and closely monitor the safety of medication to ensure rational clinical use. This study provides new ideas for the treatment of CRKP infection, but further clinical research is needed to verify its effectiveness and safety.